Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002208 | A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC | PHASE3 | COMPLETED | 400 | — | — | - | - | Jun 24, 2005 | 15 | United States |
| NCT00002220 | Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir | PHASE3 | COMPLETED | 120 | — | — | - | - | Jun 24, 2005 | 11 | United States |
| NCT00002406 | A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients | PHASE3 | COMPLETED | 350 | — | — | - | - | Jun 24, 2005 | 29 | United States |
| NCT00002410 | A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients | PHASE3 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 41 | United States, Puerto Rico |
| NCT00002235 | A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors | PHASE2 | COMPLETED | 6 | — | — | - | - | Jun 24, 2005 | 5 | United States |
| NCT00002361 | Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors | PHASE2 | COMPLETED | 30 | — | — | - | - | Jun 24, 2005 | 8 | United States |
| NCT00002351 | A Study of L-735,524 in HIV-Positive Children and Adolescents | PHASE1 | COMPLETED | 12 | — | — | - | - | Jun 24, 2005 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Indinavir sulfate | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
| Efavirenz | DRUG | - |
| Levocarnitine | DRUG | - |
| Adefovir dipivoxil | DRUG | - |
| Nelfinavir mesylate | DRUG | - |
| Ritonavir | DRUG | - |
Inclusion Criteria Patients must have: * HIV-1 seropositive status. * CD4 count greater than 100 cells/mm3. * Viral RNA above 10,000 copies/mL. * Consent from parent or guardian if less than 18 years of age. Exclusion Criteria Prior Medication: Excluded: * Prior therapy with protease inhibitor...